Today: Today, Revance Therapeutics Inc. (RVNC) Research Coverage Started at Aegis

Today, Revance Therapeutics Inc. (RVNC) Research Coverage Started at Aegis

Equities researchers at Aegis started coverage on shares of Revance Therapeutics Inc. (NASDAQ:RVNC) in a report released on Tuesday, The Fly reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also weighed in on the company. Zacks Investment Research lowered Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 10th. Brean Capital restated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, August 5th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $36.37.

Revance Therapeutics (NASDAQ:RVNC) opened at 17.60 on Tuesday. The firm has a 50-day moving average price of $15.79 and a 200-day moving average price of $15.46. The company’s market cap is $501.86 million. Revance Therapeutics has a 52 week low of $12.35 and a 52 week high of $40.40.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.25. Revance Therapeutics had a negative return on equity of 37.31% and a negative net margin of 28,187.33%. During the same period last year, the company posted ($0.81) EPS. Equities research analysts anticipate that Revance Therapeutics will post ($3.21) EPS for the current fiscal year.

In other Revance Therapeutics news, CEO L Daniel Browne sold 12,000 shares of Revance Therapeutics stock in a transaction on Friday, November 25th. The stock was sold at an average price of $17.92, for a total transaction of $215,040.00. Following the completion of the transaction, the chief executive officer now owns 208,449 shares in the company, valued at $3,735,406.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 31.15% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in RVNC. JPMorgan Chase & Co. boosted its position in shares of Revance Therapeutics by 9.9% in the second quarter. JPMorgan Chase & Co. now owns 3,327,022 shares of the biopharmaceutical company’s stock worth $45,247,000 after buying an additional 298,448 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Revance Therapeutics by 7.8% in the second quarter. Bank of New York Mellon Corp now owns 2,118,558 shares of the biopharmaceutical company’s stock worth $28,812,000 after buying an additional 152,383 shares during the last quarter. Polar Capital LLP boosted its position in shares of Revance Therapeutics by 13.0% in the third quarter. Polar Capital LLP now owns 1,319,871 shares of the biopharmaceutical company’s stock worth $21,392,000 after buying an additional 151,329 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of Revance Therapeutics by 10.3% in the third quarter. BlackRock Fund Advisors now owns 1,317,731 shares of the biopharmaceutical company’s stock worth $21,360,000 after buying an additional 123,376 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Revance Therapeutics by 11.3% in the second quarter. Vanguard Group Inc. now owns 783,706 shares of the biopharmaceutical company’s stock worth $10,659,000 after buying an additional 79,366 shares during the last quarter.

About Revance Therapeutics

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Related posts

Leave a Comment